drugset / Trial / NCT06601218

Impact of Daily Oral Cannabis Doses in Patients With Cancer

NCT06601218 ↗

Phase 1 Recruiting 80 enrolled Shanna Babalonis, PhD
RandomizedParallel-groupQuadruple-blindBasic science

Summary

This study will enroll patients with cancer and participants will be randomized to receive one dose of cannabis for approximately 4 months. There is a 3/4 (or 75%) chance that a participant will receive an active cannabis dose in the study. There is a 1/4 (or 25% chance) that a participant will receive a placebo dose (meaning a blank dose/no cannabis/no active drug). The goals of this study are to determine 1) the safety and tolerability of cannabis in individuals with cancer and 2) if cannabis can help with the side effects of cancer and cancer treatment - including nausea and vomiting, appetite, pain, sleep, and quality of life.

Timeline

Start
2025-06-17
Primary completion
2029-12-01
Completion
2030-12-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator CBD Unknown 15 mg Oral
Comparator THC Unknown 5 mg Oral
Comparator THC Unknown 15 mg Oral

Indications